Pfizer to Purchase Biohaven Pharmaceuticals for $11.6 Billion
Pfizer Inc. said it is going to be purchasing the Biohaven Pharmaceutical Holding Co. for a sum of 11.6 billion dollars in cash for the purpose of gaining an approved treatment for the migraine headaches. Pfizer is also going to pay 148.50 dollars a share for all of the New Haven, which is a Connecticut-based […]
Continue Reading